CHICAGO — Patients treated with mirvetuximab require close follow-up with an ophthalmologist due to the potential for corneal toxicity, according to a study.
In a poster presented at the American Academy of Ophthalmology meeting, Filippos Vingopoulos, MD, and colleagues sought to determine how the drug might be affecting the eyes of their patients. Mirvetuximab soravtansine (Elahere, ImmunoGen) was approved in 2022 for ovarian cancer and has a black box warning for ocular toxicity, according to the poster.
Vingopoulos and colleagues followed 36 eyes of 18 patients for approximately 6